Novel Synthetic Anticoagulants to Treat Blood Clots

Filed in archive Drugs, Vaccines and Therapeutics , Genomics, Proteomics and Bioinformatics on November 16, 2007

Researchers have designed three new molecules called molecules called sulfated DHPs which can inhibit key enzymes that play a major role in clotting disorders, and could lead to novel therapies to treat clots in the lungs and those localized deep in the body in areas such as the legs.

The team demonstrated that the molecules were able to inhibit the ability of critical enzymes involved with the cascade of events involved in blood clotting. Specifically, the molecules prevent the normal action of thrombin and factor Xa, which are the critical enzymes targeted by current anticoagulant therapy.

"We have identified a new mechanism that may prevent clotting. This approach may result in new drugs for the treatment of thrombotic disorders, including pulmonary embolism, deep vein thrombosis and more," said Desai.

In comparison to currently available anticoagulation drugs such as heparins and warfarins, these new anti-clotting therapies may result in reduced hospital stays for patients, fewer side effects, and possibly an overall cost reduction in therapy as these synthetic molecules can be produced inexpensively.

Image: An image of the enzyme that is targeted by the sulfated DHPs, the new molecules designed by Desai's team. The new molecules bind to thrombin (exosite II).
Source: VCU